歌礼制药-B(01672)：歌礼将携ASC30口服片、ASC30注射剂和ASC31与ASC47联合疗法的研究结果亮相2025年肥胖周

Core Viewpoint - The company announced plans to present multiple obesity drug candidates, including ASC30 and the ASC31 and ASC47 combination therapy, at the 2025 ObesityWeek® in Atlanta, Georgia [1] Group 1 - The presentation will be in the form of a poster at the ObesityWeek® event [1] - The founder and CEO, Dr. Wu Jinzi, expressed excitement about the ongoing progress of their small molecule and peptide obesity pipeline [1] - The advancements reflect the company's commitment to developing highly differentiated obesity treatment solutions [1]